Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 590 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 5-FU with leucovorin Clear all
Terminated Phase 3 Interventional

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

NCT05111626
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions
Bemarituzumab, Nivolumab, Chemotherapy, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
37
States / cities
Phoenix, Arizona • Cerritos, California • Downey, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 30, 2026, 2:15 AM EDT
Recruiting Phase 1 Interventional

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

NCT04361708
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma
Interventions
Oxaliplatin, Docetaxel, Leucovorin, Irinotecan, 5-Fluorouracil
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Cancer

NCT00003956
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fluorouracil, leucovorin calcium, lonafarnib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 2 Interventional

Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma

NCT00176774
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Irinotecan, 5-Fluorouracil, Leucovorin, Tetrathiomolybdate
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies

NCT00625092
View directory record Official record
Conditions
Peritoneal Cavity Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin, cytoreductive surgery
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 30, 2026, 2:15 AM EDT
Not listed Phase 2 Interventional

FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma

NCT02037048
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Gastric Cardia, Stage IIIA Esophageal Cancer, Stage IIIB Esophageal Cancer, Stage IIIC Esophageal Cancer
Interventions
oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, radiation therapy, carboplatin, paclitaxel
Drug · Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 2 Interventional

Molecularly Tailored Therapy for Pancreas Cancer

NCT01888978
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gem-OX, Gem-5FU, Gem-Tax, Modified FOLFOX-6, Ox-Tax, FOLFIRI, Tax-Iri
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Olney, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

NCT00002524
View directory record Official record
Conditions
Lymphoma
Interventions
Bleomycin Sulfate, Filgrastim, Cisplatin, Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride (DOX), Etoposide, Fluorouracil, Ifosfamide, Leucovorin calcium, Methotrexate, Methylprednisolone, Pentamidine, Prednisone, Trimethoprim-Sulfamethoxazole, Vincristine Sulfate, Zidovudine (AZT), Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2005
U.S. locations
2
States / cities
Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

A Study of ABT-165 in Subjects With Solid Tumors

NCT01946074
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
paclitaxel, FOLFIRI, ABT-165, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Results available

Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer

NCT01905150
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
G-FLIP, G-FLIP-DM, Vitamin C
Drug · Dietary Supplement
Lead sponsor
Bruckner Oncology
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 1Phase 2 Interventional

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

NCT01488552
View directory record Official record
Conditions
Stage IV Pancreatic Cancer
Interventions
Gemcitabine, nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin, mFOLFIRI
Drug · Genetic
Lead sponsor
Pancreatic Cancer Research Team
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
Scottsdale, Arizona • Burbank, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 2 Interventional

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

NCT01467115
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel
Radiation · Drug · Biological
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 30, 2026, 2:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

NCT07705919
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fluorouracil, Gadolinium-Chelate, Gemcitabine, Irinotecan, Leucovorin Calcium, Nab-paclitaxel, Oxaliplatin, Point-of-care portable perfusion phantom (P4)
Procedure · Drug · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 30, 2026, 2:15 AM EDT
Terminated Phase 2 Interventional Results available

Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer

NCT01307956
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Stage IIA Esophageal Cancer, Stage IIB Esophageal Cancer
Interventions
Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium, Oxaliplatin, Panitumumab, Pharmacological Study, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Other · Biological + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

NCT03785873
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Nivolumab, Nanoliposomal-Irinotecan, 5-Fluorouracil, Leucovorin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Ann Arbor, Michigan • Grand Rapids, Michigan • Salt Lake City, Utah + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

NCT02620865
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
Aldesleukin, Antibody Therapy, Fluorouracil, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Oxaliplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Sargramostim
Biological · Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 30, 2026, 2:15 AM EDT
Terminated Phase 1 Interventional

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

NCT02648711
View directory record Official record
Conditions
Solid Tumors
Interventions
CRLX101, Bevacizumab, mFOLFOX6
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients

NCT02826486
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
BL-8040, Pembrolizumab, Chemotherapy
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Scottsdale, Arizona • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 30, 2026, 2:15 AM EDT
Recruiting Phase 2 Interventional

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

NCT05462496
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Biopsy, FOLFIRINOX, Ciprofloxacin, Metronidazole, Pembrolizumab, Surgical Resection
Procedure · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 30, 2026, 2:15 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

NCT05825066
View directory record Official record
Conditions
Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Interventions
Nab paclitaxel, Gemcitabine, Radiological Assessments, mFOLFIRINOX
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer

NCT00052910
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, epirubicin hydrochloride, fluorouracil, leucovorin calcium, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
527
States / cities
Anniston, Alabama • Mobile, Alabama • Scottsdale, Arizona + 357 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 30, 2026, 2:15 AM EDT
Recruiting Not applicable Interventional

Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma

NCT07340151
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas
Interventions
Surgical resection
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 30, 2026, 2:15 AM EDT
Not listed Phase 1Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer

NCT00003001
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, leucovorin calcium
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2008 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Early Phase 1 Interventional

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

NCT01821612
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
oxaliplatin, irinotecan, leucovorin, 5-fluorouracil, capecitabine, radiation, surgery, gemcitabine
Drug · Radiation · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
La Jolla, California • Chicago, Illinois • Evanston, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 30, 2026, 2:15 AM EDT